WithdrawnPhase 4

Fidaxomicin to Prevent Clostridium Difficile Colonization

Stopped: Study not performed

United States0Started 2012-09

Plain-language summary

The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥ 18 years old * On broad spectrum antimicrobials * Anticipated length of stay of \> 48 hours after enrollment * A non-ICU inpatient Exclusion Criteria: * Pregnant * Expected to die within 7 days * Have previously been enrolled in this trial or a trial of an investigational agent to treat CDI, and/or are on monotherapy with an antimicrobial generally considered not to increase the risk of CDI (vanc, macrolides, tetracyclines, trimethoprim/sulfamethoxazole, aminoglycosides, colistin, linezolid, nitrofurantoin, metronidazole)

What they're measuring

Clostridium difficile

Timeframe: At discharge from hospital (average of 7 days after enrollment in study)

Trial details

NCT IDNCT01552668

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-12

View on ClinicalTrials.gov More Clostridium Difficile Infection trials